6 days Ago By ABMN Staff
Wellington Management Group LLP purchased a new position in GlycoMimetics, Inc. ( NASDAQ:GLYC – Free Report ) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,413,402 shares of the biotechnology company’s stock, valued at approximately $352,000.
GlycoMimetics Stock Performance Shares of GLYC stock opened at $0.22 on Tuesday. The business has a fifty day moving average of $0.
25 and a 200 day moving average of $0.26. GlycoMimetics, Inc.
has a 1 year low of $0.14 and a 1 year high of $2.47.
GlycoMimetics ( NASDAQ:GLYC – Get Free Report ) last announced its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.
16) by $0.05. Equities research analysts anticipate that GlycoMimetics, Inc.
will post -0.08 EPS for the current year. Wall Street Analyst Weigh In Check Out Our Latest Research Report on GlycoMimetics GlycoMimetics Company Profile ( Free Report ) GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.
It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. Featured Articles Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics, Inc.
( NASDAQ:GLYC – Free Report ). Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter .
.
